Aptus Pharma (APPL) Q4 FY26 Revenue More Than Doubles in Q4, But Profit Lags Behind
The pharmaceutical company's sales surged 118% year-on-year, but a sharp contraction in profitability reveals the cost of rapid scaling.
Aptus Pharma's Q4 FY26 revenue soared to ₹32.2 crore, more than doubling from a year ago. However, net profit grew at half that pace as operating expenses surged, compressing margins significantly.
For a fast-growing pharmaceutical company, the tension between scaling sales and preserving profitability defines the quarter. Aptus Pharma delivered on the first, with revenue more than doubling year-on-year, but saw its net profit margin shrink as the costs of that expansion bit into earnings.
Revenue for the quarter ended March 2026 surged 117.6% to ₹32.2 crore, while net profit rose 60.3% to ₹2.87 crore. The full year told a similar story: revenue nearly doubled to ₹46.57 crore, but profit growth of 49% lagged behind. The company's net profit margin for the quarter fell to 8.9%, down 320 basis points from the same period last year.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ4 FY26 | Same quarter LYQ4 FY25 |
|---|---|---|
| Revenue (₹ Cr) | 32.2YoY +118% | 14.8 |
| Profit (₹ Cr) | 2.87YoY +60% | 1.79 |
| Net Profit Margin (%) | 8.9YoY -26% | 12.1 |
Why Margins Contracted on Higher Sales
The gap between top-line and bottom-line growth points directly to rising costs. According to a report by ScanX, operating expenses grew faster than gross profit in FY26. Employee benefits rose 46% and other expenses surged 77%, reflecting investments in a larger sales force and deeper market penetration.
This is the cost of scaling an asset-light, marketing-focused model. The company, which relies on contract manufacturing, is pushing its portfolio of over 250 formulations into more retail outlets. While this drives volume, the associated promotional and distribution costs are weighing on profitability for now.
The Cash Flow Conundrum
A critical watchpoint is cash generation. Data from SectorAlpha indicates that over the last three years, Aptus Pharma's operations used more cash than they brought in. In FY26, operating cash flow was negative ₹5.6 crore against a profit of ₹4.62 crore.
Live Chart
· APPL
(BSE)
ISIN: INE15XJ01010
This stems from a lengthening working capital cycle, where inventory sits for over 230 days and customers take nearly 150 days to pay. As sales explode, more cash gets tied up in the business, a natural challenge for a company stocking shelves and offering trade credit to win market share.
Building for a Pan-India Presence
Management is betting this investment phase will pay off. The investor presentation cited by Arthneeti states an aim for double-digit revenue growth in FY27, driven by new launches and market expansion. The long-term vision is a pan-India presence by 2030.
To support this, the company is raising funds and planning a new manufacturing facility in Gujarat to bring some production in-house. The strategic roadmap targets having own manufacturing constitute 20% of the business by 2028, which could eventually strengthen margins and supply chain control.
Key Points
- Revenue growth dramatically outpaced profit growth in Q4 FY26, with sales up 118% year-on-year but profit up 60%.
- The net profit margin contracted by 320 basis points to 8.9%, pressured by steep rises in employee and other operating expenses.
- The company's asset-light, expansion-focused model has led to negative operating cash flow as working capital requirements balloon.
- Management is targeting sustained double-digit revenue growth and is planning capacity expansion to support its pan-India ambitions.
Hexa Perspective
Aptus Pharma's quarter illustrates the classic growth-investment trade-off. The revenue leap confirms commercial traction and an effective marketing model. However, the margin compression and cash consumption show that this growth is currently expensive.
The investment case now hinges on operating leverage. If the sales force and distribution network, once built, can drive volumes without a proportionate rise in costs, margins should recover. The planned move toward partial own manufacturing could also help in the medium term. Until then, investors are paying for growth today while watching for proof that it can translate efficiently into cash tomorrow.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.